Transmissible spongiform encephalopathies in Australia

Authors

  • Alison Boyd Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne, Parkville, Vic 3052
  • Ashley Fletcher Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne
  • James S Lee Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne
  • Victoria Lewis Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne
  • Colin L Masters Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne
  • Steven J Collins Australian National Creutzfeldt-Jakob Disease Registry, Department of Pathology, The University of Melbourne

DOI:

https://doi.org/10.33321/cdi.2001.25.41

Keywords:

Transmissible spongiform encephalopathies, TSE, Creutzfeldt-Jakob disease, CJD, vCJD

Abstract

The Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR) commenced surveillance in September 1993 as part of the Commonwealth's response to 4 cases of pituitary hormone (gonadotrophin)-associated Creutzfeldt-Jakob disease (CJD). With the passage of time, the Registry has become responsible for ascertaining all human transmissible spongiform encephalopathies (TSE; also known as prion diseases) within Australia since 1970. Included in the spectrum of diseases monitored are classical (sporadic, genetic, and health care acquired) CJD, and variant CJD (vCJD), first reported in 1996 in the United Kingdom. Variant CJD has not yet been diagnosed in Australia. Final classification of persons with suspected human prion disease is based upon all available clinical, investigational and pathological information. Ascertainment methods are diverse and include prompted, half-yearly personal communications from neurologists and neuropathologists, death certificate searches, and morbidity separation coding searches of major hospital, and State and Territory databases. More recently, referral for diagnostic CSF 14-3-3 protein testing (performed by the ANCJDR) has considerably increased prospective notifications of suspect cases. As at September 2001 there were 460 cases on the register; 237 definite cases, 168 probable and 55 incomplete cases awaiting final classification. Commun Dis Intell 2001;25:248-253.

Downloads

Download data is not yet available.

References

Prusiner S B. Proc Natl Acad Sci 1998;95:13,363-13,383.

Allars M. Inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease. Canberra: Australian Government Publishing Service, 1994. 815 pp.

Brown P, Preece M, Brandel J-P, Sato T, McShane L, Zerr I, et al. Latrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000:55;1075-1081.

Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D. Possible person-to person transmission of Creutzfeldt-Jakob disease. N EngI J Med 1974;290:692-693.

Thadani V, Penar PL, Partington J, Kalb R, Janssen R, Schonberger LB, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. J Neurosurg 1988;69:766-769.

Koch TK, Berg BO, DeArmond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. N Engl J Med 1985;313:731-733.

Cochius E, Bums RJ, Blumbergs PC, Mack K, Alderman CP. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust N Z J Med 1990;20:592-593.

Windl O, Dempster M, Estibeiro JP, et al. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variations in the PRNP gene. Hum Genet 1996;98:259-264.

Masters CL, Harris JO, Gajdusek DC, Gibbs CJ, Jr, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188.

Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575-582.

Steinhoff BJ, Racker S, Herrendorf G, Weber T, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neur 1996;53:162-166.

Collins S, Boyd A, Fletcher A, Gonzales M, McLean CA, Byron K, et al. Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 2000:7;203-208.

Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease Neurology 2000;55:811-815.

Australian Bureau of Statistics: August 1994 The Labour Statistics Australia, The Australian Government Publishing Service, 1994.

Australian Bureau of Statistics: March 1994 Labour Force Experience Australia, The Australian Government Publishing Service, 1994.

Raubertas RF, Brown P, Cathala F, Brown I. The question of clustering of Creutzfeldt-Jakob disease. Am J Epidemiol 1989;129:146-154.

Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor NIN, Thomas DJ, et al. Investigation of variant Creutzfeld-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-189.

Collins S, Law MG. Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999;353:693-697.

Downloads

Published

30/11/01

How to Cite

Boyd, Alison, Ashley Fletcher, James S Lee, Victoria Lewis, Colin L Masters, and Steven J Collins. 2001. “Transmissible Spongiform Encephalopathies in Australia”. Communicable Diseases Intelligence 25 (November):248-52. https://doi.org/10.33321/cdi.2001.25.41.

Most read articles by the same author(s)

1 2 3 > >>